Loading...

TRDA ENTRADA THERAPEUTICS INC US FDA Inspections 8-K Filing

NTRD

TRD

ENTRADA THERAPEUTICS INC

(TRDA)

2025 8-K

Show Summary

Show Summary

Financial Statements

Workforce Reductions

Clinical Trial Authorization

Financial Results

Clinical Trial Authorization

Financial Update

Financial Results

Financial Results

Securities Purchase Agreement

Update on ENTR-601-44

Annual Meeting and Amendmen...

Financial Results Announcement

Financial Results Announcement

Management Change

Resignations and Appointments

Update on ENTR-601-44

Financial Results Announcement

Amendment to License Agreem...

Sales Agreement

Clinical Trial Announcement

Appointment of Director

Financial Results Announcement

Clinical Trial Authorization

Resignation and Annual Meeting

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Strategic Collaboration and...

External Links:

On February 24, 2025, Entrada Therapeutics announced that the FDA lifted the clinical hold on its drug ENTR-601-44, allowing it to proceed with a Phase 1b study for treating Duchenne muscular dystrophy.

AI Assistant

ENTRADA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.